“Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell.” It affects bone marrow.
Researchers at Mayo think that introducing a strain of measles into a cancer patient has ‘cured’ her condition.
“Two patients in the study received a single intravenous dose of an engineered measles virus (MV-NIS) that is selectively toxic to myeloma plasma cells. Both patients responded, showing reduction of both bone marrow cancer and myeloma protein. One patient, a 49-year-old woman, experienced complete remission of myeloma and has been clear of the disease for over six months.”
The paper goes on to state,
“In their article, the researchers explain they were reporting on these two patients because they were the first two studied at the highest possible dose, had limited previous exposure to measles, and therefore fewer antibodies to the virus, and essentially had no remaining treatment options.”
Is it safe to say that measles vaccines would prevent treatment of this condition in this way?
What other diseases are vaccinations preventing us from curing? And how long has this been known? The theory has, in fact, been posited since before vaccines were commonly administered.
“Oncolytic virotherapy – using re-engineered viruses to fight cancer – has a history dating back to the 1950s. Thousands of cancer patients have been treated with oncolytic viruses from many different virus families (herpesviruses, poxviruses, common cold viruses, etc.). However, this study provides the first well-documented case of a patient with disseminated cancer having a complete remission at all disease sites after virus administration. ”
“A major factor of eligibility is that patients have no detectable measles antibody. If this is present, it prevents the vaccine from working. About a third of all myeloma patients tested will have this lack of measles antibody, regardless of whether they have had measles before or have been vaccinated.”
“Two tests are run to see if patients are measles antibody-negative.”
Perhaps we will need an anti-vaccine vaccine if we end up with a treatable cancer.
“Dr. Kapoor, in turn, has informed us that the principal investigators leading the Phase 2 trial have confirmed that there were, indeed, no responses to the vaccine therapy observed in the first 12 patients treated in the Phase 2 portion of the trial. “